Immucell Cp (ICCC) 7.02 $ICCC
ImmuCell Announces First Quarter 2016 Financial Results
Marketwired - Wed May 11, 3:16PM CDT
PORTLAND, ME--(Marketwired - May 11, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results for its first quarter ended March 31, 2016.
ICCC: 7.02 (+0.16)
ImmuCell to Announce First Quarter 2016 Financial Results
Marketwired - Wed May 04, 12:15PM CDT
Conference Call Scheduled for Wednesday, May 11, 2016 at 4:30 PM EST
ICCC: 7.02 (+0.16)
ImmuCell Appoints Elizabeth Williams Vice President of Manufacturing Operations
Marketwired - Mon Apr 04, 4:41PM CDT
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the hiring of Ms. Elizabeth L. Williams as Vice President of Manufacturing Operations.
ICCC: 7.02 (+0.16)
ImmuCell Announces Full Year 2015 Financial Results
Marketwired - Wed Feb 10, 3:05PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results for its fourth quarter and year ended December 31, 2015.
ICCC: 7.02 (+0.16)
ImmuCell to Announce 2015 Financial Results
Marketwired - Thu Feb 04, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, will report financial results for the fourth quarter and year ended December 31, 2015 after the market closes on Wednesday, February 10, 2016. The Company has scheduled a conference call that same day Wednesday, February 10, 2016 at 4:30 PM ET to review the results.
ICCC: 7.02 (+0.16)
ImmuCell raises USD5.9m from public offering
M2 - Thu Feb 04, 3:00AM CST
Animal health company ImmuCell (NasdaqCM:ICCC) reported on Wednesday the completion of its public offering of 1,123,810 common stock at a price of USD5.25 per share.
ICCC: 7.02 (+0.16)
ImmuCell Corporation Announces Closing of $5.9 Million Public Offering of Common Stock
Marketwired - Wed Feb 03, 9:45AM CST
ImmuCell Corporation ("ImmuCell" or the "Company"
(NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the closing of a previously announced underwritten public offering of 1,123,810 shares of common stock at a price to the public of $5.25 per share (the "Offering" .
ICCC: 7.02 (+0.16)
BUYINS.NET: NVAX, DST, MSL, ICCC, HBAN, UBNK, Expected to Trade Higher After Bullish Insider Trading
M2 - Tue Feb 02, 9:04AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Novavax Inc (NASDAQ:NVAX), DST Systems Inc (NYSE
ST), MidSouth Bancorp Inc (NYSE:MSL), ImmuCell Corp (NASDAQ:ICCC), HUNTINGTON BANCSHARES INCORPORATED (NASDAQ:HBAN), United Financial Bancorp Inc (NASDAQ:UBNK) are all expected to go Higher as Buy signals have been generated by top insider trading patterns.
HBAN: 9.50 (+0.04), MSL: 10.51 (+0.06), NVAX: 7.32 (-0.06), ICCC: 7.02 (+0.16), UBNK: 13.15 (-0.03), DST: 123.33 (-0.33)
ImmuCell prices USD5.9m in public offering
M2 - Mon Feb 01, 3:45AM CST
Animal health company ImmuCell (NasdaqCM:ICCC) said on Friday that it has priced its public offering of 1,123,810 shares of its common stock.
ICCC: 7.02 (+0.16)
ImmuCell Corporation Announces Pricing of $5.9 Million Public Offering of Common Shares
Marketwired - Fri Jan 29, 6:30AM CST
ImmuCell Corporation ("ImmuCell" or the "Company" (NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the pricing of its previously announced underwritten public offering of 1,123,810 shares of common stock (the "Offering" at a price to the public of $5.25 per share. Net proceeds to the Company from the Offering are expected to be approximately $5.3 million, after deducting underwriting commissions and other expenses related to the Offering.
ICCC: 7.02 (+0.16)
ImmuCell Corporation Announces Proposed Public Offering of Common Stock and Preliminary Full Year 2015 Results
Marketwired - Thu Jan 28, 4:53PM CST
ImmuCell Corporation ("ImmuCell" or the "Company" (NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced a proposed registered underwritten public offering of its common stock, subject to market and other conditions.
ICCC: 7.02 (+0.16)
ImmuCell Acquires Certain Assets From Minnesota Firm
Marketwired - Wed Jan 06, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC), a rapidly growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced that it has acquired certain business assets from DAY 1(TM) Technology, LLC of Minnesota.
ICCC: 7.02 (+0.16)
ImmuCell Enters Into New Contract With Norbrook
Marketwired - Tue Dec 22, 7:00AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced that it has entered into a Product Development & Contract Manufacture Agreement with Norbrook Laboratories Limited of Newry, Northern Ireland (Norbrook), a global leader in the development of revolutionary veterinary and animal health medicine, covering the final formulation and sterile-filling services for Mast Out®.
ICCC: 7.02 (+0.16)
ImmuCell Announces First Quarter 2016 Financial Results
Marketwired - Wed May 11, 3:16PM CDT
PORTLAND, ME--(Marketwired - May 11, 2016) - ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results for its first quarter ended March 31, 2016.
ICCC: 7.02 (+0.16)
ImmuCell to Announce First Quarter 2016 Financial Results
Marketwired - Wed May 04, 12:15PM CDT
Conference Call Scheduled for Wednesday, May 11, 2016 at 4:30 PM EST
ICCC: 7.02 (+0.16)
ImmuCell Appoints Elizabeth Williams Vice President of Manufacturing Operations
Marketwired - Mon Apr 04, 4:41PM CDT
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the hiring of Ms. Elizabeth L. Williams as Vice President of Manufacturing Operations.
ICCC: 7.02 (+0.16)
ImmuCell Announces Full Year 2015 Financial Results
Marketwired - Wed Feb 10, 3:05PM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results for its fourth quarter and year ended December 31, 2015.
ICCC: 7.02 (+0.16)
ImmuCell to Announce 2015 Financial Results
Marketwired - Thu Feb 04, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, will report financial results for the fourth quarter and year ended December 31, 2015 after the market closes on Wednesday, February 10, 2016. The Company has scheduled a conference call that same day Wednesday, February 10, 2016 at 4:30 PM ET to review the results.
ICCC: 7.02 (+0.16)
ImmuCell raises USD5.9m from public offering
M2 - Thu Feb 04, 3:00AM CST
Animal health company ImmuCell (NasdaqCM:ICCC) reported on Wednesday the completion of its public offering of 1,123,810 common stock at a price of USD5.25 per share.
ICCC: 7.02 (+0.16)
ImmuCell Corporation Announces Closing of $5.9 Million Public Offering of Common Stock
Marketwired - Wed Feb 03, 9:45AM CST
ImmuCell Corporation ("ImmuCell" or the "Company"
(NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the closing of a previously announced underwritten public offering of 1,123,810 shares of common stock at a price to the public of $5.25 per share (the "Offering" . ICCC: 7.02 (+0.16)
BUYINS.NET: NVAX, DST, MSL, ICCC, HBAN, UBNK, Expected to Trade Higher After Bullish Insider Trading
M2 - Tue Feb 02, 9:04AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Novavax Inc (NASDAQ:NVAX), DST Systems Inc (NYSE
ST), MidSouth Bancorp Inc (NYSE:MSL), ImmuCell Corp (NASDAQ:ICCC), HUNTINGTON BANCSHARES INCORPORATED (NASDAQ:HBAN), United Financial Bancorp Inc (NASDAQ:UBNK) are all expected to go Higher as Buy signals have been generated by top insider trading patterns. HBAN: 9.50 (+0.04), MSL: 10.51 (+0.06), NVAX: 7.32 (-0.06), ICCC: 7.02 (+0.16), UBNK: 13.15 (-0.03), DST: 123.33 (-0.33)
ImmuCell prices USD5.9m in public offering
M2 - Mon Feb 01, 3:45AM CST
Animal health company ImmuCell (NasdaqCM:ICCC) said on Friday that it has priced its public offering of 1,123,810 shares of its common stock.
ICCC: 7.02 (+0.16)
ImmuCell Corporation Announces Pricing of $5.9 Million Public Offering of Common Shares
Marketwired - Fri Jan 29, 6:30AM CST
ImmuCell Corporation ("ImmuCell" or the "Company"
(NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced the pricing of its previously announced underwritten public offering of 1,123,810 shares of common stock (the "Offering" at a price to the public of $5.25 per share. Net proceeds to the Company from the Offering are expected to be approximately $5.3 million, after deducting underwriting commissions and other expenses related to the Offering. ICCC: 7.02 (+0.16)
ImmuCell Corporation Announces Proposed Public Offering of Common Stock and Preliminary Full Year 2015 Results
Marketwired - Thu Jan 28, 4:53PM CST
ImmuCell Corporation ("ImmuCell" or the "Company"
(NASDAQ: ICCC), an animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced a proposed registered underwritten public offering of its common stock, subject to market and other conditions. ICCC: 7.02 (+0.16)
ImmuCell Acquires Certain Assets From Minnesota Firm
Marketwired - Wed Jan 06, 7:01AM CST
ImmuCell Corporation (NASDAQ: ICCC), a rapidly growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced that it has acquired certain business assets from DAY 1(TM) Technology, LLC of Minnesota.
ICCC: 7.02 (+0.16)
ImmuCell Enters Into New Contract With Norbrook
Marketwired - Tue Dec 22, 7:00AM CST
ImmuCell Corporation (NASDAQ: ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced that it has entered into a Product Development & Contract Manufacture Agreement with Norbrook Laboratories Limited of Newry, Northern Ireland (Norbrook), a global leader in the development of revolutionary veterinary and animal health medicine, covering the final formulation and sterile-filling services for Mast Out®.
ICCC: 7.02 (+0.16)
